127 related articles for article (PubMed ID: 639561)
1. Therapeutic application of iodine-125 labeled iododeoxyuridine in an early ascites tumour model.
Bloomer WD; Adelstein SJ
Curr Top Radiat Res Q; 1978 Jan; 12(1-4):513-25. PubMed ID: 639561
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of locoregional delivery of radiolabeled iododeoxyuridine and thymidylate synthase inhibitor in a hepatoma model.
Chi KH; Wang HE; Chen FD; Chao Y; Liu RS; Chou SL; Wang YS; Yen SH
J Nucl Med; 2001 Feb; 42(2):345-51. PubMed ID: 11216535
[TBL] [Abstract][Full Text] [Related]
3. Reutilization of 125I-UdR during growth of a solid mammary carcinoma: implications for the 125I-UdR loss technique.
Porschen R; Porschen W; Mühlensiepen H; Feinendegen LE
Strahlenther Onkol; 1987 Nov; 163(11):723-8. PubMed ID: 3686335
[TBL] [Abstract][Full Text] [Related]
4. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
5. Biological toxicity of Auger emitters: molecular fragmentation versus electron irradiation.
Hofer KG; Keough G; Smith JM
Curr Top Radiat Res Q; 1978 Jan; 12(1-4):335-54. PubMed ID: 639556
[TBL] [Abstract][Full Text] [Related]
6. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
7. Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design.
Narra VR; Howell RW; Harapanhalli RS; Sastry KS; Rao DV
J Nucl Med; 1992 Dec; 33(12):2196-201. PubMed ID: 1460515
[TBL] [Abstract][Full Text] [Related]
8. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats.
Kassis AI; Wen PY; Van den Abbeele AD; Baranowska-Kortylewicz J; Makrigiorgos GM; Metz KR; Matalka KZ; Cook CU; Sahu SK; Black PM; Adelstein SJ
J Nucl Med; 1998 Jul; 39(7):1148-54. PubMed ID: 9669385
[TBL] [Abstract][Full Text] [Related]
9. Cell survival and cytogenetic responses to 125I-UdR in cultured mammalian cells.
Chan PC; Lisco E; Lisco H; Adelstein SJ
Curr Top Radiat Res Q; 1978 Jan; 12(1-4):426-35. PubMed ID: 565273
[TBL] [Abstract][Full Text] [Related]
10. Efficient mutation induction by 125I and 131I decays in DNA of human cells.
Whaley JM; Little JB
Radiat Res; 1990 Jul; 123(1):68-74. PubMed ID: 2371380
[TBL] [Abstract][Full Text] [Related]
11. 5-(125I)-iododeoxyuridine and the Auger effect: biological consequences and implications for therapy.
Bloomer WD; Adelstein SJ
Pathobiol Annu; 1978; 8():407-21. PubMed ID: 364377
[TBL] [Abstract][Full Text] [Related]
12. Biological consequence of nuclear versus cytoplasmic decays of 125I: cysteamine as a radioprotector against Auger cascades in vivo.
Rao DV; Narra VR; Howell RW; Sastry KS
Radiat Res; 1990 Nov; 124(2):188-93. PubMed ID: 2247599
[TBL] [Abstract][Full Text] [Related]
13. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
15. Chromosome damage in Chinese hamster cells produced by 125I-UdR at the site of its incorporation.
Hughes WL; Weinblatt AC; Prensky W
Curr Top Radiat Res Q; 1978 Jan; 12(1-4):453-71. PubMed ID: 565274
[TBL] [Abstract][Full Text] [Related]
16. Cell loss from viable and necrotic tumour regions measured by 125I-UdR.
Porschen R; Porschen W; Mühlensiepen H; Feinendegen LE
Cell Tissue Kinet; 1983 Nov; 16(6):549-56. PubMed ID: 6627346
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of radio- and chemotoxic effects of 125I-UdR on tumour growth and host survival.
Porschen R; Porschen W; Mühlensiepen H; Feinendegen LE
Radiat Environ Biophys; 1985; 24(3):219-26. PubMed ID: 4034927
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
19. Preclinical animal studies with radioiododeoxyuridine.
Kassis AI; Adelstein SJ
J Nucl Med; 1996 Apr; 37(4 Suppl):10S-12S. PubMed ID: 8676195
[TBL] [Abstract][Full Text] [Related]
20. Fractionated radioimmunotherapy using low doses of iodine-131 labeled anti-CEA monoclonal antibody after tumor volume reduction.
Tian J; Ding Y; Zhang J; Cao L; Yin D
Chin Med J (Engl); 2000 Jan; 113(1):53-8. PubMed ID: 11775212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
